Updated Guidelines Recommend Rubraca for Some Prostate Cancer Patients

Updated Guidelines Recommend Rubraca for Some Prostate Cancer Patients
Only a couple of weeks after Rubraca (rucaparib) was approved for the treatment of prostate cancer, the National Comprehensive Cancer Network (NCCN) has updated its guidelines recommending this PARP inhibitor as an option for select prostate cancer patients in the U.S. According to Clovis Oncology, which makes Rubraca, the NCCN recommends Rubraca as a "treatment option for patients with mCRPC [metastatic castration-resistant prostate cancer] and a pathogenic BRCA1 or BRCA2 mutation (...) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy." Also, "if the patient is not fit for chemotherapy, rucaparib [Rubraca] can be considered even if taxane-based therapy has not been given," the guidelines state. The NCCN Clinical Practice Guidelines in Oncology are a comprehensive set of guidelines that provide detailed recommendations for the sequential management of cancer patients based on the best available evidence. They are considered the standard guide for clinical decisions and, according to the NCCN, are the most frequently updated guidelines available in any area of medicine. The Rubraca recommendation is classified as Category 2A, meaning there is uniform consensus from the NCCN (based on lower-level evidence) that Rubraca is appropriate for the described indication. It was based on findings from the TRITON2 Phase 2 trial (NCT02952534), in which Rubraca led to promising response rates and duration of responses. Based on these results, the treatment received conditional approval by the U.S. Food and Drug Administration (FDA) for mCRPC patients with BRCA mutations who previously received an androgen receptor inhibitor and taxane-based chemotherapy. “We are pleased that the NCCN has acknowledged the importanc
Subscribe or to access all post and page content.